Antithrombin concentrate during pregnancy in congenital antithrombin deficiency a single-center experienceBruzzese, Antonella; Santoro, Cristina; Baldacci, Erminia; Ferretti, Antonietta; Pieroni, Simone; Serrao, Alessandra; Foà, Robin; Chistolini, AntonioBlood Coagulation & Fibrinolysis: September 2019 - Volume 30 - Issue 6 - p 304–307 doi: 10.1097/MBC.0000000000000835 SHORT COMMUNICATION Buy Abstract Author InformationAuthors Article MetricsMetrics Pregnancy carries a high risk of thromboembolic complications, especially in the postpartum period. This risk is particularly high in women with inherited thrombophilias, among these antithrombin deficiency seems to carry the highest risk. In this case, the use of low molecular weight heparin (LMWH) is recommended, while the use of antithrombin concentrate is controversial. We report our experience of seven pregnancies occurred in five women: two, with a personal and familiar history negative for venous thromboembolism, were treated with LMWH during pregnancy and antithrombin concentrate immediately before and after the delivery. The other three women had a personal and familiar history positive for venous thromboembolism and were treated with LMWH and antithrombin concentrate during all the pregnancy and the postpartum period. No thromboembolic or hemorrhagic complications were observed in both groups, demonstrating that our strategy could be safe and effective. Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome Italy Correspondence to Antonella Bruzzese, Hematology, Department of Translational and Precision Medicine, Sapienza University, Via Benevento 6, 00161 Rome, Italy Tel: +39 06 857951; fax: +39 06 44241984; e-mail: firstname.lastname@example.org Received 17 January, 2019 Revised 12 May, 2019 Accepted 4 June, 2019 Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.